A 30-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy in Dyslipidemic Subjects With Stage 3 Chronic Kidney Disease.

Trial Profile

A 30-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy in Dyslipidemic Subjects With Stage 3 Chronic Kidney Disease.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Oct 2012

At a glance

  • Drugs Choline fenofibrate; Rosuvastatin
  • Indications Dyslipidaemias
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 04 Oct 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 09 Jun 2011 Actual initiation date (Jun 2008) added as reported by ClinicalTrials.gov.
    • 09 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top